AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved ...

AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.

The UK-Swedish pharma giant has shared readouts from key portfolio assets such as Enhertu, Tagrisso and Etcamah.

SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a ...

Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche ...

AstraZeneca Plc’s breast cancer pill failed to delay disease progression more than the standard treatment in a late-stage ...

The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

Sept 1 (Reuters) - AstraZeneca and China's Hutchmed said on Tuesday that a late-stage trial of a combination of their cancer drugs Tagrisso and Orpathys significantly improved progression-free ...

AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ...

AstraZeneca AZN has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen involving its ATK inhibitor Truqap (capivasertib) in certain patients with ...